8-K: Aprea Reports Q3 2025 Results, Clinical Progress & Cash Runway

Aprea Therapeutics announced its third quarter 2025 financial results and provided updates on its WEE1 and ATR inhibitor clinical programs, extending its cash runway into Q4 2026.

Summary

• Aprea Therapeutics reported an operating loss of $3.1 million for the third quarter ended September 30, 2025, an improvement from an operating loss of $4.1 million in the comparable period of 2024.
• The net loss for Q3 2025 was $3.0 million ($0.47 per basic share), compared to a net loss of $3.8 million ($0.64 per basic share) in Q3 2024.
• Cash and cash equivalents stood at $13.7 million as of September 30, 2025, a decrease from $22.8 million as of December 31, 2024.
• The company projects its current cash and cash equivalents will be sufficient to fund operations into the fourth quarter of 2026.
• In the Phase 1 ACESOT-1051 trial for APR-1051 (WEE1 kinase inhibitor), 3 out of 4 patients at Dose Level 6 (100 mg once daily) achieved stable disease, per RECIST v1.1, in heavily pretreated gastrointestinal and gynecologic malignancies.
• Dose escalation for APR-1051 has advanced to Dose Level 7 (150 mg once daily), with the compound showing a manageable safety profile, primarily Grade 1 or 2 gastrointestinal events and fatigue.
• For ATRN-119 (ATR kinase inhibitor), the Recommended Phase 2 Dose (RP2D) of 1,100 mg once daily was identified in the ABOYA-119 dose-escalation study.
• Enrollment in the monotherapy dosing arms of the ABOYA-119 trial has been strategically paused to explore potential combination studies, including with radiation or checkpoint inhibitors.
• Research and Development (R&D) expenses decreased to $1.6 million in Q3 2025 from $2.8 million in Q3 2024, primarily due to lower study start-up activities and reduced expenses for the ABOYA-119 trial.
• General and Administrative (G&A) expenses decreased to $1.5 million in Q3 2025 from $1.6 million in Q3 2024, mainly due to a decrease in insurance costs.

Sentiment

Score: 7

Explanation: The company reported positive clinical progress for both lead candidates, including early signs of efficacy and RP2D identification, which are significant milestones. Financial results show reduced losses and an extended cash runway, indicating prudent management. However, it remains a clinical-stage company with no revenue, and future capital raises are implied by the warrant structure and going concern risk.

Positives

• Operating loss and net loss decreased in Q3 2025 compared to Q3 2024, indicating improved financial efficiency.
• Cash runway extended into the fourth quarter of 2026, providing financial stability for ongoing clinical programs.
• APR-1051 (WEE1 inhibitor) demonstrated early signs of anti-tumor activity, with 3 out of 4 patients achieving stable disease at Dose Level 6 in heavily pretreated cancer patients.
• APR-1051 exhibited a manageable safety profile, with mostly Grade 1 or 2 adverse events.
• The Recommended Phase 2 Dose (RP2D) for ATRN-119 (ATR inhibitor) was successfully identified, establishing a clear path for future development.
• The company is actively exploring combination strategies for both APR-1051 and ATRN-119, which could expand their clinical impact and market potential.
• Decreases in both Research and Development (R&D) and General and Administrative (G&A) expenses reflect effective cost management.
• Robust global intellectual property protection is in place for both ATR and WEE1 inhibitor programs, safeguarding future commercialization.

Negatives

• Cash and cash equivalents decreased from $22.8 million as of December 31, 2024, to $13.7 million as of September 30, 2025, reflecting ongoing cash burn.
• The company continues to operate at a net loss, which is typical for a clinical-stage biopharmaceutical company but indicates no current revenue generation from product sales.
• Enrollment in the monotherapy dosing arms of the ATRN-119 trial has been paused, suggesting a potential shift away from monotherapy development or challenges in achieving desired efficacy as a single agent.

Risks

• Risks related to the success, timing, and cost of ongoing clinical trials and anticipated clinical trials for current product candidates, including the ability to fully fund disclosed clinical trials without material changes to projected expenses.
• Futility analyses, presentations at conferences, data reported in abstracts, and receipt of interim or preliminary results are not necessarily indicative of the final results of ongoing clinical trials.
• Uncertainty regarding the ability to predict clinical outcomes based on preclinical and early clinical results.
• Risks related to the company's ability to continue as a going concern.
• Other risks, uncertainties, and factors described under 'Risk Factors, Management's Discussion and Analysis of Financial Condition and Results of Operations' in SEC filings.

Future Outlook

Aprea Therapeutics anticipates achieving near-term inflection points and catalysts, including safety/efficacy data for APR-1051 in Q1 2026 and completion of its dose escalation in Q2 2026. A clinical update for ATRN-119 is expected in Q4 2025, following the October 2025 RP2D determination. The company is also evaluating optimal strategic partnerships and exploring combination strategies for ATRN-119 with radiation or checkpoint inhibitors, and for APR-1051 with checkpoint inhibitors.

Management Comments

• "We are pleased with the continued progress in our development programs, as the emerging data on both of our clinical assets demonstrate evidence of activity." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "For APR-1051, our WEE1 kinase inhibitor, we're encouraged by early signs of anti-tumor activity to date in the ongoing ACESOT-1051 trial, including 3 out of 4 patients with stable disease in the 100 mg once daily cohort." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "For ATR-119, identifying the recommended Phase 2 dose for the once daily (QD) dosing provides a solid foundation for next-stage development, and we are now considering potential combination strategies, with radiation or checkpoint inhibitors, that could expand its clinical impact." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "These developments reinforce Aprea's differentiated DDR approach and our commitment to helping patients with value creating clinical catalysts anticipated in 2026." Oren Gilad, Ph.D., President and Chief Executive Officer.

Industry Context

Aprea Therapeutics operates in the precision oncology space, focusing on DNA Damage Response (DDR) inhibition, a growing area in cancer therapeutics. Their approach of exploiting cancer cell vulnerabilities while minimizing damage to healthy cells aligns with the industry trend towards targeted therapies and personalized medicine. The exploration of combination therapies with checkpoint inhibitors and radiation reflects a broader industry strategy to enhance efficacy and overcome resistance in various cancer types, particularly in areas of high unmet medical need like Cyclin E over-expression and DDR-related gene mutations.

Comparison to Industry Standards

• APR-1051 is designed to potentially solve tolerability challenges of the WEE1 class and achieve improved clinical activity compared to other programs currently in development, positioning it as a potentially 'best-in-class' candidate.
• ATRN-119 is described as a 'first-in-class macrocyclic ATR inhibitor,' suggesting a novel mechanism or structural advantage compared to other ATR inhibitors in development.
• The company's focus on biomarker-defined cancers (e.g., Cyclin E over-expression, FBXW7, CCNE1, KRASG12V + TP53 alterations for WEE1; DDR-related gene mutations for ATR) is consistent with the precision oncology trend seen across the industry, aiming for higher response rates in specific patient populations.
• The observed stable disease in heavily pretreated patients for both compounds, while early, suggests potential efficacy in challenging patient populations, which is a key benchmark for novel oncology agents.

Stakeholder Impact

• Shareholders: Potential for value creation through clinical catalysts in 2026, but also dilution risk from warrants and potential future capital raises. Continued net losses impact shareholder equity.
• Patients: Continued development of innovative treatments for cancers with high unmet medical needs, offering new therapeutic options.
• Employees: Continued employment and focus on clinical development programs.
• Creditors/Investors: Extended cash runway provides stability, but ongoing losses and reliance on future financing remain considerations.

Next Steps

• Continue dose escalation for APR-1051, currently in Dose Level 7 (150 mg once daily), with the goal of identifying doses that maximize therapeutic benefit while maintaining an acceptable safety profile.
• Evaluate APR-1051 in combination with checkpoint inhibitors in future studies to address unmet medical needs across distinct patient populations.
• Consider combination studies for ATRN-119, potentially with radiation in patients with HPV+ head and neck cancer, and with I/O agents and antibody-drug conjugates.
• Achieve near-term inflection points and catalysts, including APR-1051 safety/efficacy data in Q1 2026 and completion of dose escalation in Q2 2026.
• Provide a clinical update for ATRN-119 in Q4 2025.
• Evaluate optimal strategic partnerships for its development programs.

Key Dates

Recommendation

Aprea Therapeutics has demonstrated encouraging early clinical activity for both APR-1051 and ATRN-119, with stable disease observed in heavily pretreated patients and the identification of a recommended Phase 2 dose for ATRN-119. The extension of the cash runway into Q4 2026 provides financial stability for the near term. However, the company remains in early-stage clinical development with no commercial products, incurring ongoing losses. While the clinical progress is positive, the shift to combination strategies for ATRN-119 and the reliance on future clinical catalysts in 2026, coupled with potential dilution from outstanding warrants and the 'going concern' risk, suggest a 'hold' position. Investors should await further, more mature clinical data and clarity on future financing before considering a stronger position.

Keywords

Aprea Therapeutics, APRE, Biopharmaceutical, Oncology, Cancer Treatment, WEE1 Inhibitor, APR-1051, ATR Inhibitor, ATRN-119, Clinical Trials, Phase 1, Drug Development, Financial Results, Q3 2025, Cash Runway, DDR Inhibition, Synthetic Lethality, Solid Tumors, Gastrointestinal Cancer, Gynecologic Cancer, HPV+ Head and Neck Cancer, ARID1A Mutation, Cyclin E Overexpression